Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Paris - Delayed Quote EUR

genOway Société anonyme (ALGEN.PA)

2.8100
+0.0295
+(1.06%)
At close: April 25 at 4:56:15 PM GMT+2

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Dr. Alexandre Fraichard Founder, GM & Director -- -- --

genOway Société anonyme

Technopark 2
31 Rue Saint Jean-de-Dieu
Lyon, 69007
France
33 4 37 65 41 00 https://www.genoway.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was incorporated in 1999 and is based in Lyon, France.

Corporate Governance

genOway Société anonyme’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events